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atural  YMDD  motif  mutations  in treatment  naïve
atients with  chronic  hepatitis  B  in  Huzhou  of
Table 1 – Relationship between natural YMDD motif
mutation and clinical feature.
Factor N Patients with YMDD
(n, %)
p-Value
HBeAg status
Positive 118 14, 11.86 >0.05
Negative 84 6, 7.14
HBV-DNA (copies/mL)
≥105 56 4, 7.14 >0.05
<105 146 16, 10.96
Genotypes
B 118 11, 9.32 >0.05
C 81 9, 11.11
was not signiﬁcantly different (p > 0.05) (Table 1). This resultastern China
ear Editor,
amivudine (LAM), a nucleoside analog, was the ﬁrst anti-HBV
rug approved for antiviral therapy in China. Long-term antivi-
al therapy with LAM may lead to drug resistance, which is
ssociated with a mutation in tyrosine-methionine-aspartic
cid-aspartic acid (YMDD) motif of the reverse transcrip-
ase in HBV-DNA genome. Several previous studies showed
hat YMDD mutations were also present in treatment-naive
hronic hepatitis B (CHB) patients, but the prevalence rates of
atural YMDD motif mutations in some reports were quite
ifferent (from 0% to 26.9%).1–4 However, the relationship
etween natural YMDD motif mutations and virus-related
haracteristics in CHB patients is also not quite clear. The aim
f present study was to assess the prevalence rate of natu-
al YMDD motif mutations and to investigate the associations
etween natural YMDD mutations and clinical factors among
AM-untreated CHB patients in Huzhou city, eastern China.
A total of 202 CHB patients who had never received antivi-
al treatment were recruited from department of infectious
iseases in Huzhou central hospital for this study. CHB was
iagnosed according to the Chinese consensus criteria. This
tudy was approved by the Ethics Committee of Huzhou cen-
ral hospital. All patients provided written informed consent.
erum HBV DNA levels were quantiﬁed using a real-time
CR kit. HBV genotypes were analyzed by genotype-speciﬁc
aqman probes using a real-time ﬂuorescence PCR. YMDD
utations were detected using speciﬁc primers for real-time
CR.
Natural YMDD mutations were found in 20 (9.9%) treatment
aive CHB patients. Among these patients, YVDD variants
ere detected in 13 cases, YIDD variants in 5 cases, and
VDD + YIDD variants in 2 cases. In this study, the rate
f natural YMDD motif mutation was not consistent with
revious studies.1–4 The reason for the discrepancy might
e due to different demographic characteristics, geograph-
cal diversion, other characteristics of study groups, and
ample sizes, as well as sensitivity of different detection
ethods.2–4
The mean age of patients were 37.8 ± 10.8 and 36.7 ± 13.2
ears for patients with and without natural YMDD motif,B/C mixed 3 0, 0.0
respectively (p > 0.05); 70% of patients with natural YMDD
motif were male compared to 68.7% of patients without natu-
ral YMDD motif (p > 0.05). Some previous studies showed that
natural YMDD motif mutation was not associated with age
and gender of patients,3–5 which is consistent with the results
of this study.
In present study, the prevalence rate of natural YMDD
mutations among HBeAg positive and HBeAg negative
patients were not signiﬁcantly different (p > 0.05) (Table 1). This
ﬁnding is contrast with some previous reports,3,4 but in line
with other reports.2 The relationship between the HBV geno-
type and natural YMDD mutations is not clearly identiﬁed.
Some previous researchers reported that most natural YMDD
motif mutations occurred in patients infected with genotype
C and its mixed forms.2,4 In contrast, our results showed no
association between natural YMDD motif mutations and HBV
genotype (p > 0.05) (Table 1).
In addition, the prevalence rate of YMDD in patients with
high HBV-DNA level (≥105 copies/mL) was higher than those
with low HBV-DNA level (<105 copies/mL), but the differenceis not consistent with previous studies, which suggested an
association between higher HBV-DNA level and increased
prevalence of natural YMDD mutations.4,5 Whether the
i s . 2 0
r
1
2
3
4
5
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).646  b r a z j i n f e c t d 
HBV-DNA level is indeed associated with higher prevalence
of YMDD mutations warrants more  studies.
This study shows that the natural YMDD motif mutations
do exist in a proportion of treatment-naive CHB patients in
eastern China. These ﬁndings suggest that it is necessary to
screen for YMDD resistance mutations before LAM therapy.
Further large-scale, multi-center and follow-up studies are
needed to elucidate the mechanism and clinical signiﬁcance
of natural YMDD motif mutations in HBV chronically infected
patients.
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